Skip to main content
Premium Trial:

Request an Annual Quote

Centogene Partners With German Universities on Dx Tools for Colon, Pancreatic Cancer

NEW YORK (GenomeWeb) – German multiomics tools firm Centogene announced today a collaboration with the medical faculties of the Universities of Greifswald and Rostock to develop diagnostic tools for personalized, immune-based treatments for colon and pancreatic tumors.

As part of the research project, Centogene will genetically profile cancer patients to identify immune-relevant mutations and identify specific biomarkers for early differential diagnosis and therapy monitoring.

The project is supported by the European Union through the European Regional Development Fund, Operational Program Mecklenburg-Vorpommern 2014-2020. Financial and other terms of the deal were not disclosed.

According to Centogene, colon and pancreatic cancer are among the most common tumors, and for pancreatic cancer, the five-year survival rate was just 9 percent in 2017.

Earlier this week, the company announced it will open its first US-based rare disease laboratory in Cambridge, Massachusetts on Aug. 1.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.